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INTRODUCTION
Donor availability remains one of the major challenges to 
the success of allogeneic hematopoietic cell transplantation 
(HSCT).   A human leukocyte antigen (HLA)-matched sib-
ling donor (MSD) or HLA-matched unrelated donor (MUD) 
can be identified for only around 50% of patients requiring 
HSCT.   HLA haploidentical related donors are quickly avail-
able and can be identified for nearly all patients.   However, 
historically, HSCT from a related donor mismatched for one 
HLA haplotype (HLA haploidentical transplantation, hap-
loHSCT) was associated with high rates of graft failure and 
graft vs. host disease (GVHD).   The Baltimore group devel-
oped post-transplant cyclophosphamide (PTCy) to overcome 
HLA barriers and omit the need for ex vivo T cell depletion 
following HSCT.   Several studies demonstrated that hap-
loHSCT with PTCy is associated with low incidences of graft 
failure, severe acute and chronic GVHD and non-relapse 
mortality (NRM).   Therefore, haploHSCT with PTCy repre-
sents a promising solution to enable all patients indicated for 
transplant who lack an HLA-matched donor to undergo allo-
geneic HCT.
As PTCy depletes proliferating cells and immune cell 
recovery depends on de novo generation rather than prolifera-
tion of mature cells in the graft, the graft cell content may 
have a lesser impact on the outcome after haploHSCT with 
PTCy.1-3   To better understand the relationship between hap-
loHSCT with PTCy and clinical outcome, we reviewed 
recent studies on immune reconstitution after T-cell replete 
haploHSCT using PTCy, although there are other approaches 
to haploHSCT using antithymocyte globulin (ATG) and 
intense immunosuppression (GIAC protocol) developed by 
the Peking group or T cell-depleted (TCD) haploHSCT using 
CD34-positive selection or CD3/CD19 cell depletion.
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As HLA haploidentical related donors are quickly available, HLA haploidentical hematopoietic stem cell transplantation (hap-
loHSCT) using high-dose post-transplant cyclophosphamide (PTCy) is now widely used.   Recent basic and clinical stud-
ies revealed the details of immune reconstitution after T-cell replete haploHSCT using PTCy.   T cells and NK cells in the graft 
proliferate abundantly at day 3 post-haploHSCT, and the PTCy eliminates these proliferating cells.   After ablation of proliferat-
ing mature cells, donor-derived NK cell reconstitution occurs after the second week; however, recovering NK cells remain 
functionally impaired for at least several months after haploHSCT.   PTCy depletes proliferating cells, resulting in the preferen-
tial accumulation of Treg and CD4+ T cells, especially the memory stem T cell (TSCM) phenotype.   TSCM capable of both self-
renewal and differentiation into effector T cells may play an important role in the first month of immune reconstitution. 
Subsequently, de novo T cells progressively recover but their levels remain well below those of donor CD4+ T cells at the first 
year after haploHSCT.   The phenotype of recovering T cells after HSCT is predominantly effector memory, whereas B cells are 
predominantly phenotypically naive throughout the first year after haploHSCT.   B cell recovery depends on de novo generation 
and they are not detected until week 4 after haploHSCT.   At week 5, recovering B cells mostly exhibit an unconventional tran-
sitional cell phenotype and the cell subset undergoes maturation.   Recent advances in immune reconstitution have improved 
our understanding of the relationship between haploHSCT with PTCy and the clinical outcome.
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Monocytes are heterogeneous and can be subdivided into 
three subpopulations, classic (CD14++CD16-), intermediate 
(CD14+CD16+) and non-classic (CD14+CD16++) mono-
cytes.   Turcotte et al. reported that a higher absolute mono-
cyte count and classic monocyte subsets at day 28 are associ-
ated with a reduced risk of relapse and treatment-related 
mortality (TRM), in addition to an improved 2-year overall 
survival (OS).4   Monocyte counts normalize by 1 month 
after conventional HSCT, whereas monocyte reconstitution 
has not been fully evaluated in the haploHSCT with PTCy 
setting.   However, in patient groups receiving haploHSCT 
using the GIAC protocol, monocyte expansion was rapid, 
reaching normal values within 30 days of transplant;5 similar 
results were observed in patients receiving T cell-depleted 
haploHSCT using CD34-positive selection or CD3/CD19 cell 
depletion.6
Neutrophil reconstitution
The median times to neutrophil recovery are 16-19 days 
and 21-23 days in peripheral blood (PB) and bone marrow 
(BM) HLA-identical sibling transplantations, respectively 
(Table 1).   The Center for International Blood and Marrow 
Transplant Research conducted a large scale comparison of 
outcomes for T cell replete haploHSCT with PTCy using 
either BM or PB grafts.   The median time to neutrophil 
recovery was 1 day slower after transplantation of BM than 
after PB (17 vs. 16 days), but there were no significant differ-
ences in the rate of neutrophil recovery at day 28.7   The simi-
lar recovery after haploHSCT with PTCy contrasts the find-
ing that neutrophil recovery occurs 4 to 6 days earlier with 
PB in the matched related and unrelated donors.8-10   Complete 
or near complete donor chimerism occurs quickly after hap-
loHSCT10,11 and there were no differences in graft failure 
rates after transplantation of BM versus PB.7
Natural killer (NK) cell reconstitution
NK cells can be divided into two main subsets based on 
CD56 and CD16 surface expression.   CD56bright/CD16neg-
low (CD56br) NK cells representing NKG2A+ KIR- are 
immature and have regulatory functions.12   Conversely, 
CD56dim/CD16pos (CD56dim) NK cells representing 
NKG2A- KIR+ are mature and have cytotoxic functions. 
NK cells are the first lymphocytes to recover after transplan-
tation and are considered powerful effector cells in HSCT in 
terms of their anti-leukemic and anti-infectious effects.   The 
impact of NK cells in HSCT has been demonstrated mainly 
in HLA-mismatched haploHSCT with in vivo (ATG) or ex 
vivo T cell depletion.13,14   To a lesser degree, in HLA-
matched T cell replete stem cell recipients, high early NK 
cell reconstitution is associated with better clinical out-
comes.15,16   Although the frequencies and absolute counts of 
circulating NK cells reach normal levels a few weeks post-
transplant, it takes much longer to mature and attain efficient 
effector functions.12,17-19   In recipients of HLA-matched 
HSCT, although reconstituting NK cells remain immature for 
more than 6 months post-transplantation, better phenotypic 
and functional reconstitution is related to better clinical 
outcomes.17,20
Robert et al. reported that although donor derived NK 
cell reconstitution occurs the second week after haploHSCT, 
recovering NK cells are a functionally exhausted subset of 
unconventional CD56dim/CD16neg NK cells whose gene 
expression profile is intermediate between conventional 
CD56br and conventional CD56dim NK cells.19   NK cells on 
days 30 and 60 are often lower in haploHSCT with PTCy 
than in HLA-matched related HSCT in which NK cell recon-
stitution occurs the first week.21   These unconventional 
CD56dim NK cells have impaired cytotoxicity and are char-
acterized by significantly increased expression of NKG2A 
compared with their counterparts in healthy donors.19 
Unconventional CD56dim NK cells express high levels of 
activating receptors and lytic granules, and an in vitro study 
revealed that the cytotoxicity of these NK cells can be 
reversed by blocking the inhibitory receptor NKG2A.
Russo et al. extensively investigated NK cell reconstitu-
tion in haploHSCT recipients with PTCy.22   At day 3 after 
transplantation, NK cells proliferated to an even greater 
extent than T cells and eliminated proliferating NK cells. 
After ablation of proliferating mature NK cells, donor 
derived NK cell reconstitution occurred 15 days after hap-
loHSCT and immature NK cells became highly prevalent. 
This suggests that NK cell recovery depends on de novo gen-
eration rather than proliferation of mature NK cells in the 
graft.   Importantly, single KIR+ NK cells, considered to 
HaploHSCT with PTCy Conventional HSCT
Monocytes by 30 days by 30 days
Neutrophils at 16-17 days PBSCT at 16-19 days
BM at 21-23 days
NK cells at the second week
(functionally exhausted)
at the first week
Conventional T cells CD8: by 30 days
CD4: over 1 year
CD8: PBSCT by 80 days
          BMT by 180 days
CD4: PBSCT/BMT over 1 year
Regulatory T cells by 15 days by 30 days
B cells at 49-77 days over 180 days
Table 1. The median times to immune cell reconstitution
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include potentially alloreactive NK cells, were also elimi-
nated by PTCy and had impaired anti-leukemic potential at 
day 30 after HSCT.   Consequently, in an extended series of 
99 cases of haploHSCT with PTCy, Russo et al. found that 
the KIR ligand mismatch model of NK cell alloreactivity did 
not correlate with any of the major HSCT end points in hap-
loHSCT with PTCy.22   The absolute counts and relative pro-
portion of mature NK cells at day 30 after HSCT may be a 
more reliable predictor of effective NK cell-mediated immu-
nosurveillance against relapse after haploHSCT with PTCy.22
These reports suggest that PTCy dampens the impact of 
KIR ligand mismatches on the HSCT outcome by eliminating 
the majority of mature alloreactive NK cells.   However, in 
several studies of haploHSCT with PTCy, KIR mismatches 
(e.g. KIR receptor ligand mismatches, the KIR B/x haplotype 
with KIR2DS2 and inhibitory KIR gene mismatch) were 
associated with lower rates of relapse and better survival,23-26 
as observed in HLA-matched donor HSCT.27,28   More 
recently, Ido et al. reported that KIR2DS1 positivity signifi-
cantly reduced the risk of both relapse and mortality in the 
complete response (CR) group, but not in the non-CR group, 
after PTCy-haploHSCT.29   Although patients with a high 
residual tumor burden require earlier exertion of graft vs. leu-
kemia (GVL) effects to control leukemia/tumor progression, 
PTCy eliminates proliferating alloreactive NK cells and NK 
cell recovery may require more than 60 days.21,22   These find-
ings regarding immune reconstitution may explain why GVL 
effects mediated by NK cells were observed when the tumor 
burden was low.
The role played by NK cells in GVHD is controversial 
and the exact NK cell-mediated mechanism for the preven-
tion of GVHD onset remains unclear.   Early studies sug-
gested the involvement of NK cells in GVHD induction or 
exacerbation.30   In both mice and humans, NK cells infil-
trated the target tissues during GVHD; studies using murine 
models based on antibody depletion or genetic change in NK 
cells demonstrated a reduction in GVHD.31-33   However, 
these approaches were unable to exclude the contribution of 
several immune cell subsets other than NK cells, including 
activated T cells,34-36 prompting further studies on the adop-
tive transfer of NK cells.   Most studies involving adoptive 
transfer of NK cells failed to induce GVHD.   Furthermore, 
Murphy et al. reported that in mice receiving splenocytes, 
activated NK cells prevented the development of GVHD.37 
This unexpected result was confirmed by several other 
reports.14,38-46   NK cells can suppress GVHD by killing acti-
vated T cells40,47 and antigen-presenting cells (APCs), which 
are necessary for T cell activation.14,46,48   In addition to their 
cytolytic potential, NK cells can alter immune responses 
through cytokine production.   Increased NK cell IFN-γ pro-
duction after HSCT in humans is associated with an 
increased incidence of acute GVHD.49   Conversely, one clin-
ical study reported that a high NK cell frequency in the first 
weeks after HSCT may prevent T cell proliferation through 
IL-10 production.50
The quality of NK cells greatly affects the incidence of 
GVHD.   Increased absolute counts and frequencies of 
NKG2A+ NK cells reduce acute GVHD by inhibiting T cell 
proliferation and activation.51   Furthermore, increased fre-
quencies of NKG2C+ NK cells are associated with a lower 
incidence of GVHD in allo-HSCT.52   Recent studies revealed 
that CMV infections/reactivations are beneficial for NK cell 
recovery after haploHSCT.   In particular, CMV can acceler-
ate NK cell maturation and induce the expansion of termi-
nally-differentiated and alloreactive CD56dim NK cells that 
have potent GVL effects.53
Innate lymphoid cells (ILC) are classified into two sub-
populations, cytotoxic-ILC and helper ILC.   The helper-ILC 
population is further subdivided into ILC1, ILC2 and ILC3, 
which functionally mirror the CD4+ Th1, Th2 and Th17 cell 
subsets, respectively.54   ILC3 is a heterogeneous cell popula-
tion that includes fetal lymphoid tissue inducer (LTi) cells, 
and two different ILC3 subsets have been identified in 
humans based on the expression of the natural cytotoxic 
receptor (NCR) NKp44.54   NCR+ ILC3 are an important 
innate source of IL-22, a potent cytokine that acts directly on 
epithelial cells to induce proliferation, survival and repair.55 
In a mouse GVHD model, the ILC frequency and IL-22 
amounts were reduced by GVHD and IL-22 deficient recipi-
ents had more acute GVHD tissue damage.56
In haploHSCT with PTCy, ILC reconstitution has not yet 
been fully evaluated.   Munneke et al. reported that ILCs dis-
appear in the weeks after conventional allogeneic HSCT, and 
that reconstitution of ILC1, ILC2 and NCR- ILC3 was slower 
than that of neutrophils and monocytes.55   After 3 months 
post-transplant, the levels of circulating ILC2 were still lower 
than those in healthy subjects.   In contrast, NCR+ ILC3 
reconstitution was apparent as early as 12 weeks after alloge-
neic HSCT, whereas such cells are not present in the circula-
tion of healthy people.55   The rapid appearance of NCR+ 
ILC3 was observed in the peripheral blood of patients who 
did not develop acute or chronic GVHD.   In addition, 
increased proportions of skin-homing ILC1 and NCR- ILC3, 
and gut homing ILC2 in patients without acute GVHD of the 
skin and gut were observed.55   ILC reconstitution is not 
affected by cyclosporine or corticosteroids,55 whereas granu-
locyte-colony-stimulating factor (G-CSF) may affect ILC3 
and NK cell differentiation in vitro.57   Furthermore, ILC 
development may be impaired in patients with acute myeloid 
leukemia (AML).58   Thus, after HSCT, ILC development 
may be affected by the presence of high residual leukemia 
burden or leukemia relapse.
Conventional T cell reconstitution
Several studies evaluated early T cell reconstitution fol-
lowing haploHSCT with PTCy.59,60   Roberto et al. reported 
that at day 3 post-haploHSCT, most CD3+ cells, particularly 
CD8+ T cells, expressed markers of proliferation (Ki-67) and 
activation.59   Both naïve T cells and memory T cells divide 
in response to allogeneic stimulation, and naïve T cells rap-
idly acquire a memory/effector-phenotype; Ki-67-positive T 
cells exhibited exclusively memory phenotypes, and naïve T 
cells were Ki-67-negative among both CD4+ and CD8+ T 
cells at day 3 post-haploHSCT.   Regulatory T cells (Tregs) 
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with a naive phenotype expressed lower markers of prolifera-
tion than conventional CD4+ T cells.   PTCy depleted prolif-
erating cells, resulting in preferential accumulation of CD4+ 
T cell and Treg following PTCy.   Among both CD4+ and 
CD8+ T cells, recipient T cells accounted for less than 10% 
of the total at day 5, disappearing by day 15 post-HSCT.60 
At day 7, recipient T cells were preferentially memory, 
whereas donor naïve T cells disappeared from circulation and 
donor cells predominantly had the memory stem T cell (TSCM) 
phenotype.   In vitro incubation of naïve T cells with allo-
APCs led to CD95 upregulation and the TSCM phenotype.59 
Cieri et al. also reported that TSCM exhibited low levels of 
apoptosis and were highly enriched at day 8 post-hap-
loHSCT.60   The serum concentration of IL-7 at day 1 was 
correlated with the number of circulating CD8+ and CD4+ 
TSCM lymphocytes.60   CD31, a marker preferentially 
expressed by early differentiated CD4+ recent thymic emi-
grant T cells, clustered predominantly within the TSCM com-
partment.   By day 30 post-HSCT, CD31 expression on 
CD4+ TSCM was significantly reduced compared with day 8, 
whereas CD31+ naïve T cells were again detectable, consis-
tent with de novo generation.   Collectively, TSCM observed 
following PTCy may originate from CD31+ CD4+ naïve T 
cells infused within the graft.   These cells were gradually 
replaced by more differentiated central memory cells and 
effector memory cells over the following weeks.   TSCM repre-
sents the earliest developmental stage of memory T cells, and 
can differentiate into large numbers of effector T cells while 
maintaining their pool size through homeostatic self-renewal. 
TSCM may play an important role in the first month of immune 
reconstitution.   Although one study of 66 patients receiving 
haploHSCT with PTCy reported that CD3 + cell counts ≥120 
cells/μL at day 30 were associated with a slightly longer OS 
and less relapse,61 the physiological roles and involvement of 
TSCM in the transplantation outcome are largely unknown.
The majority of T cells that recover within the first 30-90 
days after haploHSCT with PTCy are derived from the donor 
naive compartment.62   Roberto et al. reported that T cells 
were undetectable in most patients up to 6 weeks post-hap-
loHSCT.59   From week 6, when mycophenolate mofetil was 
discontinued, CD3+ cells (particularly CD8+ T cells) 
increased (Fig. 1).   CD8+ T cells recovered earlier than 
CD4+ T cells after haploHSCT, leading to an inverted ratio 
of CD4+ /CD8+ cells, as observed after HLA-matched 
HSCT.   In myeloablative conditioning (MAC) haploHSCT 
with PTCy, CD8 + T cells neared normal levels by 60 days 
and achieved them by 180 days post-transplant.63   This 
CD4+ and especially CD8+ T cell recovery was comparable 
with that after T cell–replete BM allografting using standard 
GVHD prophylactic regimens.64   The generation of new 
naïve T cells by resumed thymic output did not begin until 
day 90 post-haploHSCT, and CD4+ thymic emigrant T cell 
or naïve T cells were absent during this time period.   At day 
90, recovering T cells predominantly exhibited a transitional 
memory, effector memory or terminal effector cell pheno-
type.   Subsequently, T cells progressively recovered up to 1 
year after haploHSCT, but remained well below normal 
donor CD4+ T cell levels at 1 year after haploHSCT.59,62   The 
low levels of thymic emigrant T cells suggested that the 
majority of T cell reconstitution in the first year after hap-
loHSCT is due to the proliferation of cells present in the graft 
rather than from de novo generation.
Fig. 1. Kinetics of T cell reconstitution after haploHSCT
At day 7, CD4+ T cells are predominantly of the memory stem T cell (TSCM) phenotype. By 
day 30 post-HSCT, CD4+ TSCM is significantly reduced, whereas CD31+ naïve T cells are 
again detectable, consistent with de novo generation. CD8 + T cells reach near normal levels 
by 60 days and achieve them by 180 days post-transplant, but CD4+ T cells remain below 
normal levels at 1 year after haploHSCT. This CD4+ and especially CD8+ T cell recovery 




Regulatory T cell (Treg) reconstitution
Kanakry et al. revealed that CD4+ Foxp3+ T cells from 
patients and from allogeneic mixed lymphocyte reactions 
expressed relatively high levels of aldehyde dehydrogenase 
(ALDH), and concluded that ALDH expression drives Treg 
resistance to Cy.   They also found that there was relative 
preservation of memory CD4+ Foxp3+ T cells after PTCy. 
Moreover, CD4+ CD45RA- Foxp3hi effector Tregs recovered 
rapidly.65   Naïve Tregs defined as CD45RO- CCR7+ 
CD45RA+ were increased in the early days following trans-
plantation,59 and Tregs significantly expanded at day 15 after 
transplantation compared with both leukapheresis samples 
and healthy controls.66   Cieri et al. reported that values of 
circulating Treg <5% at day 15 after transplantation were 
predictive of subsequent GVHD.   Another study also found 
that effector Tregs achieved normal donor levels at day 30.63 
Nakamae et al. compared immune reconstitution after hap-
loHSCT with PTCy with that after conventional HCT and 
found that the Treg to conventional CD4+ T-cell ratio was 
significantly higher until day 90 in haploHSCT with PTCy.21
Using a murine haploHSCT with PTCy model, Matsuoka 
et al. evaluated early lymphocyte reconstitution.67   Of note, 
Ki-67+ proliferating cells, including conventional T cells and 
Tregs, were depleted by Cy intervention; however, surviving 
T cells after Cy intervention had significantly higher BCL-2 
expression levels than control recipients.   Based on the 
increased anti-apoptotic elements, T cells in PTCy-treated 
recipients underwent aggressive homeostatic proliferation 
and the CD4 T cell subset, particularly Tregs, eclipsed that 
the of control recipient by day 14.   CD8+ T cell proliferation 
after PTCy was less aggressive than the CD4 T cell prolifera-
tion, resulting in a higher ratio of Tregs to CD8 T cells in 
PTCy recipients than in controls.68   At day 21 after HSCT, 
the number of Tregs in the spleen was significantly higher in 
PTCy-treated recipients than in the non-PTCy controls.68
γδ T -cell reconstitution
As they do not require further peripheral maturation or 
extensive clonal expansion to initiate their effector-functions, 
γδ T cells are rapid responders to pathogens and tumors. 
Absolute counts of γδ T cells do not influence the incidence 
or severity of GVHD69,70 and meta-analysis demonstrated that 
high γδ T cell values are associated with less disease relapse 
and fewer viral infections.69   However, these is no impact of 
γδ T cells on infection or relapse after conventional trans-
plant and their effect is context dependent, with a greater 
impact in the T cell-depleted transplant setting.69   γδ T cell 
reconstitution is evaluated mainly in recipients receiving αβ 
and CD19-depleted grafts.71-73   The majority of recovering γδ 
T cells in the first weeks have a CD27+ CD45RA- central 
memory phenotype and the same γδ T cell clones found in 
the donor are present in the recipient after the transplant.70,74 
This suggests that γδ T cell recovery depends on peripheral 
expansion of graft-derived mature γδ T cells.   Subsequently, 
central memory γδ T cells are replaced by naïve CD27+ 
CD45RA+ γδ T cells originating from donor infused HSCs 
within 14-60 days post-transplantation.70,73,75
The dominant subset of circulating γδ T cells in the 
peripheral blood of healthy subjects expresses the Vδ2 TCR 
paired with the Vγ9 TCR, whereas the minority express the 
Vδ1 TCR.   After haploHSCT using the GIAC protocol, the 
recovery of Vδ2+ T cells was continuously delayed for at 
least 180 days after HSCT mainly, which was significantly 
correlated with the development of EBV reactivation.76,77 
On the other hand, several studies in recipients receiving αβ 
and CD19 depleted grafts reported that the recovery of the 
CDR3 of the TCR δ chain was almost complete 2 months 
after haploHSCT71-73 and that reactivation of CMV (but not 
other viruses) was associated with the expansion of Vδ1+ T 
cells.73   In haploHSCT with PTCy, γδ T cell reconstitution 
remains to be fully characterized.
B-cell reconstitution
After immature B cells leave the bone marrow and enter 
the peripheral blood and lymphoid organs, they go through a 
transitional stage before becoming fully mature naïve B cells. 
The phenotype of recovering T cells after HSCT is predomi-
nantly effector memory, in contrast, B cells are predomi-
nantly phenotypically naive throughout the first post-trans-
plant year.78   One study found that B cells were not detected 
until day 28 after haploHSCT79 and recovering B cells were 
mostly Ki-67-negative at week 8, suggesting that B cell 
recovery depends on de novo generation rather than prolifera-
tion of cells present in the graft.   B cells achieved normal 
donor frequency between days 49 and 77 post-hap-
loHSCT.63,79   The phenotype of recovering B cells was 
largely immature/transitional (CD38 bright CD10+) until 
around day 60, when transitional B cells decreased. 
Subsequently, transitional cells were replaced by mature B 
cells.   The majority of B cells are naïve up until 180 days 
after haploHSCT.   The proportion of memory B cells is ini-
tially low, but can reach levels similar to that of marrow 
donors.79   Repertoires of post-transplant B cells are highly 
diverse.78
Roberto et al. investigated the steps of B cell maturation 
after haploHSCT and observed three distinct transitional sub-
sets during reconstitution based on CD5 and CD21 surface 
expression: T1 (CD5+ CD21-), T2 (CD5+ CD21+) and CD5- 
CD21+.79   In addition, they reported an additional CD5- 
CD21- stage, named T0, which precedes the aforementioned 
T1 and T2 transitional stages.   At week 5, recovering B cells 
mostly exhibited a T0 or, in smaller proportion, T1 pheno-
type.   Subsequently, T0 cells progressively decreased, 
whereas T2 and CD5- CD21+ cells increased.   The differen-
tiation status of transitional B cells differed substantially 
among BM donors and patients up to 8 -14 weeks post-hap-
loHSCT.   Transitional B cell subsets underwent a maturation 
process, as they progressively upregulated the naive markers 
IgD, IgM and CD217.   The surface expression of IgM at 
week 15 was significantly higher than that of transitional B 
cells from donors.79
B cells affect chronic GVHD.80,81   Sarantopoulos et al. 
demonstrated that delayed recovery of B-cell homeostasis 
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and the persistence of high B cell activation factor /B-cell 
ratios are associated with an activated CD27+ B-cell pool in 
human chronic GVHD.   Recent studies suggested that 
donor-derived follicular helper T cells (Tfh) play an impor-
tant role in chronic GVHD pathogenesis by promoting the 
differentiation from naïve B cells into germinal center B 
cells, which may produce anti-host antibodies.   Using a 
murine haploHSCT with PTCy model, Matsuoka et al. evalu-
ated the reconstitution of B cells, Tfh cells and Tregs.82   Tfh 
cells were present at a low frequency in PTCy -treated recipi-
ents, whereas Tregs and B cells were present at higher fre-
quencies than in the non- PTCy controls.   This suggests that 
PTCy can induce the expansion of Tregs and increase naïve 
B cell recovery without causing the early emergence of Tfh 
cells in lymph nodes, resulting in diverse T and B cell 
reconstitution.
A subset of regulatory B cells (Bregs) in mice negatively 
regulate T cell immune responses through the secretion of 
regulatory cytokines, such as IL-10, as well as through direct 
cell-cell contact.   Khoder et al. demonstrated that B cells 
with immunoregulatory properties are enriched within both 
the CD19+ IgM+ CD27+ memory and CD19+ CD24hi 
CD38hi transitional B-cell subsets in healthy human donors 
and IL-10-producing Bregs are less abundant in patients with 
chronic GVHD.83   Further studies are needed to assess Breg 
reconstitution after PTC.
Dendritic cell (DC) reconstitution
Della Porta et al. analyzed the kinetics of reconstitution 
for two circulating dendritic cell (DC) subsets.   The first was 
myeloid DCs, which express the myeloid antigens; CD33, 
CD13 and CD11c, and drive Th-1 differentiation.   The sec-
ond was lymphoid or plasmacytoid DCs, which lack myeloid 
markers and induce Th-2 differentiation.   They found that a 
normal myeloid DC count was reached on day 365 after 
HSCT, whereas plasmacytoid DCs remained at a lower fre-
quency than that in the controls.84   Chang et al. reported the 
slower recovery of DCs, including myeloid DC1s (MDC1s), 
myeloid DC2s (MDC2s) and plasmacytoid DCs, at 15 and 30 
days post-transplant in T cell replete haploHSCT using the 
GIAC protocol than in HLA-matched recipients.85   MDC1s 
and plasmacytoid DCs reached normal levels at one year in 
both HLA-matched and haploHSCT recipients.   Due to the 
impact of ATG on DCs, the early reconstitution of MDC1s, 
MDC2s and plasmacytoid DCs was significantly delayed 
after haploHSCT using the GIAC protocol.85   In another 
study investigating haploHSCT using the GIAC protocol, the 
recipients had markedly reduced proportions of DCs, 
myeloid DCs and plasmacytoid DCs for at least 180 days 
post-haploHSCT compared with healthy subjects.76   In hap-
loHSCT with PTCy, DC reconstitution has not yet been fully 
evaluated.
CONCLUSION
Although recent basic and clinical studies revealed the 
details of immune reconstitution after T-cell replete haploHSCT 
using PTCy, how haploHSCT using PTCy can reduce the risk 
of GVHD and/or relapse remains unclear.   Advances in 
immune reconstitution will improve our understanding of the 
relationship between haploHSCT with PTCy and the clinical 
outcome, and further improve outcomes after HSCT.
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